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Conclusions: The new convective model is a marked 
improvement over the current HTPS. Explicit modelling of 
fluids is particularly important when the bladder or its direct 
surroundings are part of the treatment target area. 
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Purpose/Objective: The prognosis of patients with high risk 
prostate cancer (PCa) is improved by adjuvant radiotherapy 
(RT) after radical prostatectomy (RP), although the 5 year 
biochemical recurrence free survival (bRFS) does not exceed 
75-80%. Hypofractionated RT allows shorter treatment time 
and is theoretically associated with an improvement in the 
probability of cure in patients with PCa. However, 
hypofractionated RT may be associated with a higher 
incidence of long-term advers effects. To date, definitive 
indications on safety and efficacy of this fractionation are 
not available, especially in patients undergoing RP. 
Therefore, aim of this study was to evaluate safety and 
efficacy of postoperative hypofractionated RT with based on 
SIB-IMRT technique. 
Materials and Methods: Patients with high-risk resected PCa 
(R1, pT3, Gleason Score > 7) were enrolled in the study. The 
dose to the prostate was 62.5 Gy (2.5 Gy / fraction). In 
patients with dissection of < 7 lymph nodes and with a risk of 
nodal involvement > 15%, prophylactic irradiation of pelvic 
lymph nodes was performed. Furthermore, according to the 
NCCN risk categories, adjuvant hormone therapy (HT) was 
prescribed (intermediate risk: 6 months; high risk: 24 
months); bRFS (PSA> 0.2 ng/ml), local control, disease-free 
and overall survival were assessed using the Kaplan-Meier 
method. Survival curves were compared by log-rank test 
(univariate analysis) and Cox Proportional Hazard Method 
(multivariate analysis, considering as covariates: stage, 
pretreatment PSA, Gleason Score, RT treatment modalities, 
HT duration). Patients were classified according to the NCCN 
2014 risk categories. 
Results: A total of 127 patients were enrolled in the study 
(R1: 83.3%, pT3-4: 81.6%, Gleason score > 7: 38.9%). The 
results of the analysis are shown in the table.  
 
Conclusions: In a phase I-II study on postoperative 
hypofractionated-accelerated RT plus HT based on risk 
factors, an acceptable incidence of acute and long-term side 
effects and an improved bRFS compared to standard 
postoperative RT were recorded. 
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Purpose/Objective: Recent studies have expanded the 
concept that the systemic inflammatory response has an 
important role in the progression of several solid tumours. 
The neutrophil-to-lymphocyte ratio (NLR), an easily 
determinable marker of systemic inflammation, has been 
associated with clinical outcome in various cancer entities. In 
the present study, we validated the prognostic relevance of 
an elevated pre-treatment NLR in a cohort of European 
patients with non-metastatic prostate cancer treated with 3D 
conformal radiotherapy. 
Materials and Methods: Data from 415 consecutive non-
metastatic prostate cancer patients treated with 3D 
conformal radiotherapy at a single tertiary academic center 
from 1999-2007 were included in this retrospective study. 
Clinical disease-free survival (DFS), distant metastases-free 
survival (DMFS), and overall survival (OS) were assessed using 
the Kaplan-Meier method. To evaluate the prognostic 
relevance, univariate and multivariate Cox regression models 
were performed for each endpoint.  
Results: Based on previous studies, an NLR cut-off value of 5 
was applied to differentiate between a low (<5) and high (≥5) 
NLR.  
In univariate analysis, the elevated NLR was significantly 
associated with decreased clinical PFS (HR 1.87, 95% CI 1.05-
3.32, p=0.033) that remained significant in the multivariate 
analysis (HR 2.53, 95%CI 1.40-4.59, p=0.002). Additionally, 
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we detected a significant correlation between an elevated 
NLR with decreased DMFS in univariate (HR 1.95, 95% CI 1.07-
3.54, p=0.029) and in multivariate analysis (HR 2.79, 95% CI 
1.49- 5.19, p=0.001). In OS analysis, the elevated NLR was 
significantly associated with decreased OS in univariate 
analysis (HR 1.79, 95% CI1.04-3.04, p=0.036) and multivariate 
analysis (HR 1.98, 95% CI 1.13-3.47, p=0.018).  
Conclusions: The NLR seems to represent an independent 
prognostic marker and should be considered for future 
individual risk assessment in patients with prostate cancer.  
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Purpose/Objective: International Prostate Symptoms Score 
(IPSS) and International Index Erectile Function (IIEF-5) were 
assessed in prostate cancer (PCa) patients (pts). We here 
compare IPSS/IIEF in active surveillance (AS) vs radical 
radiotherapy (RT). 
Materials and Methods: Questionnaires filled in at 4 followup 
(fup) times: T0=enrollment in AS/RT; T1=10 mos after 
diagnosis (fairly corresponding to 3 mos from RT end); T2=12 
mos from diagnosis/6 mos from RT and T3= 24 mos from 
diagnosis/18 mos from RT. RT population also had 
measurement at RT end.  
In the RT population the subset of pts without androgen 
deprivation (AD) was selected for IIEF analysis. 
IPSS was divided into 3 classes: =0-7 (mild symptoms, symp), 
8-19 (moderate symp), 20-35 (severe symp). IIEF was 
separated into 3 levels: 22-25 (no erectile dysfunction, ED), 
12-21 (mild/moderate ED), 0-11 (severe ED). 
Significant changes over time were investigated with Z-test 
for proportions. 
Results: Cohorts: 247 pts (AS), 494 pts (RT IPSS), 202 pts (RT 
no AD). Median age: 64 (AS) vs 72 (RT) yrs. 
IPSS significantly greater in high prostate volumes (>65cc, 
p=0.007), IIEF declines with age (continuous, p=0.001). 
IPSS changes by baseline class stratification (fig 1a-1b): 
different behavior for AS vs RT in no and mild symp class: AS 
pts show a slight worsening with time (ageing?) while RT pts 
show a marked worsening at RT end, which is then recovered 
till AS levels are reached. Notably, pts with severe symp at 
baseline display partial resolution of their symp in both 
cohorts, probably due to prescription of drug for benign 
prostatic hyperplasia in AS and AD in RT.  
Mean IIEF stratified by basal class+age (fig 1c-1d): youngest 
pts without ED show substantial worsening in RT, which was 
persistent with time. Corresponding AS pts reported just 
small declining. Older pts: effect of ageing more evident in 
AS, with substantial decline over time. RT pts show combined 
effect of ageing+RT, with worsening without recover. Ageing 
effect less evident in pts with mild baseline ED: here decline 
at time of rebiopsy (in AS) but then initial levels recovered. 
Worsening in RT seems here entirely due to RT (younger pts 
exhibiting greater decline). 
Significant decline in IIEF, defined as severe ED in pts with 
IIEF-5>11 at T0, was always significantly higher in RT, about 
13% vs 40% (p<0.05). 
 
 
 
Conclusions: IPSS showed a significant worsening in RT at 
short fup (acute phase of radioinduced toxicity). Due to the 
timing of onset of late urinary toxicity, these results (limited 
to 18 mos fup) cannot be considered conclusive for this 
endpoint.  
Greater worsening of ED in RT, especially when younger pts 
are considered. For older pts effect of ageing sums up with 
dose, especially for initially potent pts.  
Comparison between AS and RT allows evaluation of 
confounding factors (ageing, psychological aspects) when 
studying ED after RT, thus allowing a more confident 
estimation of the role of RT in the onset of this kind of 
morbidity.  
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